A new study examined the combination of the common immunotherapy drug pembrolizumab (Keytruda) with all-trans retinoic acid (ATRA), a chemotherapy drug that targets myeloid-derived suppressor cells.

Remission is when there are no or very low levels of cancerous cells. The drug all-trans retinoic acid (ATRA) can help promyelocytes mature into white blood cells by eliminating the PML-RARα protein.

they could not show that ATRA directly altered MDSC levels. He noted that while their data suggest this to be how the drugs worked, there may be other explanations as well. Dr. Marjorie Zettler ...